The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck

Michael E. Kupferman, Mark W. Kubik, Carol R. Bradford, Francisco J. Civantos, Kenneth O. Devaney, Jesus E. Medina, Alessandra Rinaldo, Sandro J. Stoeckli, Robert P. Takes, Alfio Ferlito

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


From 18% to 35% of cutaneous melanomas are located in the head and neck, and nearly 70% are thin (Breslow thickness ≤ 1 mm). Sentinel lymph node biopsy (SLNB) has an established role in staging of intermediate-thickness melanomas, however its use in thin melanomas remains controversial. In this article, we review the literature regarding risk factors for occult nodal metastasis in thin cutaneous melanoma of the head and neck (CMHN). Based on the current literature, we recommend SLNB for all lesions with Breslow thickness ≥ 0.75 mm, particularly when accompanied by adverse features including mitotic rate ≥ 1 per mm2, ulceration, and extensive regression. SLNB should also be strongly considered in younger patients (e.g. < 40 years old), especially in the presence of additional adverse features. All patients who do not proceed with sentinel lymph node biopsy must be carefully followed to monitor for regional relapse.

Original languageEnglish (US)
Pages (from-to)226-232
Number of pages7
JournalAmerican Journal of Otolaryngology - Head and Neck Medicine and Surgery
Issue number2
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck'. Together they form a unique fingerprint.

Cite this